Clinical Trial

Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer

Study acronym: BrachyTRACKS
Recruiting
View on ClinicalTrials.gov →
Summary
This is an observational single-center trial for patients with localized prostate cancer suitable for High Dose Rate (HDR) brachytherapy as monotherapy. This study takes a multi-omics approach to study the mechanism of action of HDR brachytherapy through metabolomics, immunological, transcriptomics, and spectroscopic profiling. The results of this study will clarify the optimal dose for HDR prostate brachytherapy by documenting the dose-response relationship seen in the changing tumor metabolites after HDR brachytherapy and investigate the immunogenicity of HDR brachytherapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-12-29; most recent amendment 2026-01-29.
Status change: Not Yet Recruiting → Recruiting 2024-04-11
Trial Details
NCT Number NCT06200974
Lead Sponsor British Columbia Cancer Agency
Collaborators: BC Cancer Foundation, University of British Columbia, Vancouver Prostate Centre
Conditions Localized Prostate Carcinoma
Enrollment 100 participants
Start Date 2024-02-01
Primary Completion 2028-03-01 (estimated)
Study Completion 2038-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-02